trials. Interim trial results suggest that donor lungs in ideal condition transported in the OCS according to protocol had a 50-percent reduction in the incidence of graft dysfunction compared to those transported in standard ice coolers.
Because an estimated 5-10 percent of donor lung offers meet “standard or ideal conditions,” the EXPAND I trial was conducted to see the effect of the OCS on lungs that were outside of the ideal scenario. The EXPAND I interim results suggested 88 percent utilization of such lungs. That means double the number of potentially transplantable organs and a reduction in the time patients spend on the waitlist. For questions regarding the OCS, please call 832-355-2285.
Baylor St. Luke’s Medical Center is the first site in the nation to begin the EXPAND II clinical trial and the first site in Texas to utilize the OCS lung platform. In the EXPAND II trial, we will compare transplantation using the OCS in extended criteria donors to the outcomes of standard ice transplantation in standard donors. For more information on this trial, please contact us at 832-355-2285.